{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Elbanna M"],"funding":["NCI NIH HHS","NIH NCI"],"pagination":["147-156"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7002017"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(1)"],"pubmed_abstract":["Receptor tyrosine kinase inhibitors have shown clinical benefit in clear cell renal cell carcinoma (ccRCC), but novel therapeutic strategies are needed. The angiopoietin/Tie2 and MET pathways have been implicated in tumor angiogenesis, metastases, and macrophage infiltration. In our study, we used trebananib, an angiopoietin 1/2 inhibitor, and a novel small-molecule MET kinase inhibitor in patient-derived xenograft (PDX) models of ccRCC. Our goal was to assess the ability of these compounds to alter the status of tumor-infiltrating macrophages, inhibit tumor growth and metastases, and prolong survival. Seven-week-old SCID mice were implanted subcutaneously or orthotopically with human ccRCC models. One month postimplantation, mice were treated with angiopoietin 1/2 inhibitor trebananib (AM"],"journal":["Molecular cancer therapeutics"],"pubmed_title":["Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma."],"pmcid":["PMC7002017"],"funding_grant_id":["P30CA082709","P30 CA082709"],"pubmed_authors":["Shen L","Rex K","Damayanti NP","Adelaiye-Ogala R","Ciamporcero E","Ku SY","Caenepeel S","Elbanna M","Chintala S","Pili R","Coxon A","Ramakrishnan S","Orillion AR","Miles KM"],"additional_accession":[]},"is_claimable":false,"name":"Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma.","description":"Receptor tyrosine kinase inhibitors have shown clinical benefit in clear cell renal cell carcinoma (ccRCC), but novel therapeutic strategies are needed. The angiopoietin/Tie2 and MET pathways have been implicated in tumor angiogenesis, metastases, and macrophage infiltration. In our study, we used trebananib, an angiopoietin 1/2 inhibitor, and a novel small-molecule MET kinase inhibitor in patient-derived xenograft (PDX) models of ccRCC. Our goal was to assess the ability of these compounds to alter the status of tumor-infiltrating macrophages, inhibit tumor growth and metastases, and prolong survival. Seven-week-old SCID mice were implanted subcutaneously or orthotopically with human ccRCC models. One month postimplantation, mice were treated with angiopoietin 1/2 inhibitor trebananib (AM","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jan","modification":"2025-04-05T15:36:44.509Z","creation":"2020-07-04T07:19:08Z"},"accession":"S-EPMC7002017","cross_references":{"pubmed":["31582532"],"doi":["10.1158/1535-7163.mct-18-1202","10.1158/1535-7163.MCT-18-1202"]}}